THIOLOGICS
LIVE

Serial Number

79115013

Owner

UCL Business plc

Attorney

Joel D. Voelzke

Filing Date

Jan 27, 2012

Add to watchlist:

No watchlists yet
View on USPTO

THIOLOGICS Trademark

Serial Number: 79115013 • Registration: 4452854

THIOLOGICS is a trademark filed by UCL Business plc on January 27, 2012. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

UCL Business plc (2 trademarks)

97 Tottenham Court Road
London W1T4TP , GB

Entity Type: 03

Trademark Details

Filing Date

January 27, 2012

Registration Date

December 24, 2013

Published for Opposition

October 8, 2013

Cancellation Date

January 27, 2022

Goods & Services

Pharmaceutical preparations, namely, polypeptide bioconjugates and polynucleic acid bioconjugates for use in diagnosis and treatment of autoimmune, cardiovascular, central nervous system, dental, dermatology, endocrine, gastrointestinal, genetic, hematology, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurological, oncology, ophthalmological, otolaryngology, psychiatric, respiratory, urogenital, urological and viral diseases and disorders in animals and humans; biological preparations, namely, polypeptide bioconjugates and polynucleic acid bioconjugates for use in diagnosis and treatment of autoimmune, cardiovascular, central nervous system, dental, dermatology, endocrine, gastrointestinal, genetic, hematology, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurological, oncology, ophthalmological, otolaryngology, psychiatric, respiratory, urogenital, urological and viral diseases and disorders in animals and humans; diagnostic preparations for medical purposes; diagnostic preparations for scientific or research use; diagnostic kits consisting primarily of antibody preparations, namely, antibody bioconjugates, namely, antibody-drug conjugates, antibody-radionuclide conjugates and antibody-imaging agent conjugates for use in diagnosis and treatment of autoimmune, cardiovascular, central nervous system, dental, dermatology, endocrine, gastrointestinal, genetic, hematology, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurological, oncology, ophthalmological, otolaryngology, psychiatric, respiratory, urogenital, urological and viral diseases and disorders in animals and humans; diagnostic kits consisting primarily of chemical products for medical diagnostic use, namely, polypeptide bioconjugates and polynucleic acid bioconjugates for use in diagnosis and treatment of autoimmune, cardiovascular, central nervous system, dental, dermatology, endocrine, gastrointestinal, genetic, hematology, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurological, oncology, ophthalmological, otolaryngology, psychiatric, respiratory, urogenital, urological and viral diseases and disorders in animals and humans; diagnostic kits consisting primarily of biochemical preparations, namely, polypeptide bioconjugates and polynucleic acid bioconjugates for use in diagnosis and treatment of autoimmune, cardiovascular, central nervous system, dental, dermatology, endocrine, gastrointestinal, genetic, hematology, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurological, oncology, ophthalmological, otolaryngology, psychiatric, respiratory, urogenital, urological and viral diseases and disorders in animals and humans

Chemicals for use in bioconjugation, reversible bioconjugation, irreversible bioconjugation, reversible cysteine protection, surface modification, and prodrug production; biochemicals, namely, polypeptides, polypeptides for in vivo applications, polypeptides for in vitro applications, polynucleic acids, polynucleic acids for in vivo applications, and polynucleic acids for in vitro applications; biomolecules, namely, proteins, peptides, antibodies, antibody fragments, antibody mimetic proteins, and polynucleic acids; chemical products for diagnostic use, namely, conjugates of polypeptides with small molecule drugs, imaging agents, and radionuclides for medical applications; biochemical preparations, namely, polypeptides, polynucleic acids, and antibodies, all for use in medical research; biochemical preparations, namely, polypeptides, polynucleic acids, and antibodies, all for use in diagnosis and treatment of disease

Scientific and technological services, namely, design and assembly of polypeptide bioconjugates and polynucleic acid bioconjugates, and design and optimization of proprietary bioconjugation technologies; biological research; chemical research and analysis; scientific advisory services relating to research and development in the field of diagnostic preparations and diagnostic products; providing scientific information and advisory services in the fields of scientific research and design, and biological and chemical research

Filing History

NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Aug 21, 2022 DENC
DEATH OF INTERNATIONAL REGISTRATION
Aug 21, 2022 DETH
TOTAL INVALIDATION PROCESSED BY THE IB
Jan 29, 2022 INNT
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Dec 23, 2021 INTS
INVALIDATION PROCESSED
Dec 23, 2021 INPC
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Oct 26, 2021 INTR
NEW REPRESENTATIVE AT IB RECEIVED
Oct 2, 2021 NREP
CANCELLED SECTION 71
Feb 26, 2021 C71T
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Dec 24, 2018 REM3
FINAL DECISION TRANSACTION PROCESSED BY IB
Jun 6, 2014 FINO
FINAL DISPOSITION NOTICE SENT TO IB
May 19, 2014 FICS
FINAL DISPOSITION PROCESSED
May 19, 2014 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Mar 24, 2014 FICR
REGISTERED-PRINCIPAL REGISTER
Dec 24, 2013 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 8, 2013 NPUB
PUBLISHED FOR OPPOSITION
Oct 8, 2013 PUBO
NOTIFICATION PROCESSED BY IB
Oct 7, 2013 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Sep 18, 2013 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Sep 18, 2013 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 18, 2013 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Aug 30, 2013 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 22, 2013 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 20, 2013 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 20, 2013 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Aug 20, 2013 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Mar 7, 2013 GNFN
FINAL REFUSAL E-MAILED
Mar 7, 2013 GNFR
FINAL REFUSAL WRITTEN
Mar 7, 2013 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 14, 2013 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 14, 2013 CRFA
ASSIGNED TO LIE
Feb 7, 2013 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 6, 2013 TROA
REFUSAL PROCESSED BY IB
Aug 30, 2012 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 7, 2012 RFCS
REFUSAL PROCESSED BY MPU
Aug 7, 2012 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 7, 2012 RFCR
APPLICATION FILING RECEIPT MAILED
Aug 7, 2012 MAFR
NON-FINAL ACTION WRITTEN
Aug 6, 2012 CNRT
ASSIGNED TO EXAMINER
Aug 3, 2012 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 3, 2012 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Aug 2, 2012 REPR